CC
AXSM icon

Cannell & Co’s Axsome Therapeutics AXSM Stock Holding History

Cannell & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$6.59M Sell
82,845
-21,345
-20% -$1.43M 0.21% 93
2023
Q3 		$7.28M Sell
104,190
-15,020
-13% -$1.12M 0.25% 93
2023
Q2 		$8.57M Hold
119,210
– – 0.28% 89
2023
Q1 		$7.35M Sell
119,210
-250,810
-68% -$16.5M 0.26% 93
2022
Q4 		$28.5M Buy
370,020
+320,680
+650% +$19.2M 1.03% 32
2022
Q3 		$2.2M Buy
49,340
+43,340
+722% +$2.17M 0.08% 120
2022
Q2 		$230K Buy
+6,000
New +$190K 0.01% 243

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cannell & Co's AXSM Position: Q4 2023 in Review

Cannell & Co reduced its Axsome Therapeutics (AXSM) stake by 20% in Q4 2023, selling an estimated $1.43M and leaving 82,845 shares worth $6.59M. The position accounts for 0.21% of the portfolio, ranked #93.

Cannell & Co first reported a position in AXSM in Q2 2022 and has held it in 7 quarters since. The position peaked at $28.5M in Q4 2022. 244 funds tracked by Wall St. Rank hold AXSM as of Q4 2023.

  • Cannell & Co held 82,845 shares of Axsome Therapeutics worth $6.59M as of Q4 2023.
  • Cannell & Co sold 21,345 Axsome Therapeutics shares in Q4 2023, an estimated $1.43M.
  • Axsome Therapeutics made up 0.21% of Cannell & Co's portfolio in Q4 2023, its #93 holding.
  • Cannell & Co first reported a position in Axsome Therapeutics in Q2 2022 and has held it in 7 quarters since.
  • Cannell & Co's Axsome Therapeutics position peaked at $28.5M in Q4 2022.
  • 244 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2023.

Based on Cannell & Co's 13F filing for Q4 2023, filed 5 Feb 2024.